公开(公告)号：US20220235141A1

公开(公告)日：2022-07-28

申请号：US17613304

申请日：2020-05-21

申请人： Pfizer Inc.

发明人： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC分类号： C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  A61P35/00

摘要： This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.

公开(公告)号：US20230250173A1

公开(公告)日：2023-08-10

申请号：US18002942

申请日：2021-06-29

申请人： Pfizer Inc.

发明人： Keith Anthony Ching ,  Craig Davis ,  Xinmeng Mu ,  Shobha Potluri ,  Yan Qu ,  Shahram Salek-Ardakani ,  Graham Thomas ,  Ji Wen

IPC分类号： C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  A61P13/02

CPC分类号： C07K16/2818 ,  C12Q1/6886 ,  A61P35/00 ,  A61P13/02 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The present disclosure describes therapies comprising a PD-1 axis binding antagonist, wherein a sample from the patient has been pre-determined to have certain biomarkers.

公开(公告)号：US20220241412A1

公开(公告)日：2022-08-04

申请号：US17613557

申请日：2020-05-20

申请人： Pfizer Inc. ,  MERCK PATENT GMBH

发明人： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC分类号： A61K39/395 ,  A61K31/519 ,  A61P35/00

摘要： This invention relates to a method for treating cancer by administering a CDK4/6 or a CDK2/4/6 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an OX40 agonist and/or a 4-1BB agonist to a subject in need thereof.

公开(公告)号：US11702474B2

公开(公告)日：2023-07-18

申请号：US17120935

申请日：2020-12-14

申请人： Pfizer Inc.

发明人： Javier Fernando Chaparro Riggers ,  Shih-Hsun Chen ,  Sheng Ding ,  Pawel Kamil Dominik ,  Shahram Salek-Ardakani ,  Jessica Lynn Stanfield ,  Thomas John Van Blarcom

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2827 ,  A61P35/00 ,  C07K16/2803 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.

公开(公告)号：US20230053328A9

公开(公告)日：2023-02-16

申请号：US17613304

申请日：2020-05-21

申请人： Pfizer Inc.

发明人： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC分类号： C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  A61P35/00

摘要： This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.